HOT: HIPEC in Ovarian Cancer as Initial Treatment

Exclusion Criteria

• •Any prior treatment modality for the diagnosis of ovarian, fallopian tube, or primary peritoneal cancerPrior surgical attempt of cytoreductive surgery
• •Stage I/II disease
• •Presence of other invasive malignancies or evidence of other cancer within the past 3 years
• •Known active acute hepatitis and confirmed diagnosis of HIV
• •Active systemic infection that requires use of parenteral antibiotics
• •History of acute coronary syndromes (ACS), within the last 6 months, according to AHA definitions
• •New York Heart Association (NYHA) Class II or higher congestive heart failure according to American Heart Association (AHA) definitions
• •Canadian Cardiovascular Society (CCS) Class II or higher angina grade according to AHA definitions
• •Uncontrolled hypertension defined as \> 140/90 and not cleared for surgery at time of consent by cardiologist
• •History of cerebral artery disease and prior stroke according to AHA definitions in the last 6 months
• •Renal insufficiency with serum creatinine level ≥1.5 times the upper limit of normal or calculated creatinine clearance \<60 ml/min
• •Patients with concurrent severe medical problems unrelated to malignancy that will preclude compliance with the study or places at an unacceptable risk for participation in the study determinate by study investigators
• •Pregnant women are excluded from this study because carboplatin is category D agent with the potential of teratogenic effects. Due to potential risk for adverse events in nursing infants secondary to treatment of the mother with carboplatin, breastfeeding should be discontinued
• •Life expectancy of \< 12 weeks